Cytokinetics’ (aficamten) met both primary endpoints in the Phase 3 ACACIA-HCM trial for non-obstructive hypertrophic cardiomyopathy (nHCM). Already approved for obstructive HCM, the drug could soon double its market.
Viridian's drug for thyroid eye disease showed strong Phase 3 results, improving eye symptoms with simple injections and possible home use.
Guggenheim rates ACRS Buy, $12 target vs $4.50 now; skin/immune drugs, trials ahead, big upside if results are good.
Biomea is testing a new diabetes pill that may fix insulin cells. Early results look strong, with big growth potential but high risk.
UCB buys Candid Therapeutics for $2B+ to develop immune disease drug that may reset immune system; rivals’ stocks rise.
Mirum’s drug volixibat reduced severe itching in PSC patients in a Phase 2 trial; next step is FDA filing in 2026.
